Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2020 | HCT in MDS: cell source and conditioning type

Fernando Barroso Duarte • 30 Aug 2020
EBMT 2020
Myelodysplastic Syndromes Antibodies Busulfan Cyclophosphamide Elotuzumab Fludarabine Melphalan

Fernando Barroso Duarte, MD, Federal University of Ceara, Clinical Hospital, Fortaleza, Brazil, discusses the influence of cell source and conditioning type on hematopoietic cell transplantation (HCT) in myelodysplastic syndromes (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Fernando Barroso Duarte

Allogeneic transplantation in elderly patients: insights from Brazilian registry data
2:23
Allogeneic transplantation in elderly patients: insights from Brazilian registry data
Fernando Barroso Duarte • 30 Mar 2025
Allogeneic transplantation for CMML from the Latin American perspective
2:20
Allogeneic transplantation for CMML from the Latin American perspective
Fernando Barroso Duarte • 30 Mar 2025
Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT
6:04
Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT
Fernando Barroso Duarte • 12 May 2023
Relevance of the IPSS-R during SCT in patients with MDS in the molecular classification era
3:31
Relevance of the IPSS-R during SCT in patients with MDS in the molecular classification era
Fernando Barroso Duarte • 13 Feb 2023

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Fernando Barroso Duarte • 6 Dec 2025
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
1:07
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
Fernando Barroso Duarte • 6 Dec 2025
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
5:58
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
Fernando Barroso Duarte • 16 Dec 2025
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
1:30
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
Fernando Barroso Duarte • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals